ANP but not BNP reflects early left diastolic dysfunction in type 1 diabetics with myocardial dysinnervation

Horm Metab Res. 2003 May;35(5):301-7. doi: 10.1055/s-2003-41306.

Abstract

Objective: We investigated whether plasma concentrations of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) reflect impaired diastolic relaxation or its improvement after ACE inhibition.

Methods: 7 long-term Type 1 diabetic patients with normal systolic but impaired diastolic function and with sympathetic myocardial dysinnervation and 10 controls were included. Exercise tolerance and maximal O 2 uptake were evaluated by bicycle exercise prior to the study. ANP, BNP and norepinephrine/epinephrine (NE/E) were determined at baseline and at 80 % .VO2 max workload and after recovery, before and following 12 weeks of treatment with fosinopril (10 mg/d).

Results: Isovolumetric relaxation time (IVRT) and A/E wave ratio were increased by 26.7 +/- 11.5 % and 54.4 +/- 26.1 % in diabetic patients as compared to controls, respectively (p < 0.02). After 12 weeks of fosinopril treatment, no differences in IVRT or A/E wave ratio were detectable between groups. ANP was enhanced in Type 1 diabetes as compared to controls (baseline: 9.2 +/- 3.0 vs. 4.5 +/- 1.1; exercise: 22.4 +/- 7.7 vs. 7.9 +/- 1.2; recovery: 20.3. +/- 4.6 vs. 9.5 +/- 2.0 fmol/ml, p < 0.02). Fosinopril treatment abolished any differences between groups. BNP plasma levels did not differ between groups and no exercise dependent changes were observed. NE- and E-increase was greater at 80 % .VO2 max work load in Type 1 diabetes than in controls (p < 0.05). Again, fosinopril abolished differences between groups.

Conclusion: In Type 1 diabetes, impaired diastolic function is associated with elevated ANP and catecholamine plasma levels that are normalized after ACE inhibition. Thus, ANP but not BNP appears to be a sensitive biochemical marker for early diastolic dysfunction in Type 1 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Atrial Natriuretic Factor / blood*
  • Biomarkers
  • Blood Glucose / metabolism
  • Blood Pressure / physiology
  • Body Mass Index
  • Cardiomyopathies / blood*
  • Cardiomyopathies / etiology
  • Cardiomyopathies / physiopathology
  • Diabetes Mellitus, Type 1 / blood*
  • Diabetes Mellitus, Type 1 / physiopathology
  • Diabetic Angiopathies / blood*
  • Diabetic Angiopathies / physiopathology
  • Diastole / physiology
  • Female
  • Fosinopril / pharmacology
  • Glycated Hemoglobin / metabolism
  • Heart / innervation*
  • Hemodynamics / drug effects
  • Humans
  • Male
  • Natriuretic Peptide, Brain / blood*

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Biomarkers
  • Blood Glucose
  • Glycated Hemoglobin A
  • Natriuretic Peptide, Brain
  • Atrial Natriuretic Factor
  • Fosinopril